Allogene Therapeutics Inc.

ALLO | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.71

+$0.02 (+1.18%)

Sep 22, 2026, 12:48 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.18%

(1D)

Rating

Updated: Aug 26, 2026

26.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $590.94M

1D Range

1.69 1.74

52W Range

1.04 4.46

Valuation (TTM)

PE -2.52

PB 1.34

EV/EBITDA -2.10

Valuation (NTM)

Forward PE N/A

Forward PEG -0.44

Price Target $6.43

Cash Flow

FCF Yield -17.6%

SBC Adj. FCF Yield -24.0%

SBC Impact -36.5%

Margins

Gross Margin -699.4%

Operating Margin -3886.1%

FCF Margin -2211.2%

Growth (CAGR)

Revenue 3Y | 5Y 215.3% | -34.5%

Dil EPS 3Y | 5Y 41.6% | 27.3%

FCF 3Y | 5Y 37.5% | 15.0%

Returns

ROA -30.1%

ROE -50.0%

ROIC -34.8%

Financial Health

Net Cash

$332.6M

Current Ratio 10.72

Interest Coverage -138.71

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of...

Sector Healthcare

Industry Biotechnology

Employees 151

IPO Date Oct 10, 2018

Website www.allogene.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$6.42

Upside

+275.44%

Buy (6)

Hold (3)

Sell (0)

Analyst Details ➞